MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571356 | Name: CDPPB
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CDPPB is a mGluR5 positive allosteric modulator. CDPPB has been shown to have positive therapeutic effects for cognitive deficits in schizophrenia and pathology in Huntington's disease, without stimulating to evoke seizures. CDPPB as well as other PAM's have potential to be nootropic drugs that enhance learning and cognitive processes, including with respect to ASD.

Chemical Structure

CDPPB
CDPPB
CAS#781652-57-1

Theoretical Analysis

MedKoo Cat#: 571356

Name: CDPPB

CAS#: 781652-57-1

Chemical Formula: C23H16N4O

Exact Mass: 364.1324

Molecular Weight: 364.41

Elemental Analysis: C, 75.81; H, 4.43; N, 15.38; O, 4.39

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
200mg USD 1,550.00 2 Weeks
500mg USD 3,150.00 2 Weeks
1g USD 4,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CDPPB
IUPAC/Chemical Name
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
InChi Key
BKUIZWILNWHFHD-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H16N4O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20/h1-15H,(H,25,28)
SMILES Code
O=C(NC1=CC(C2=CC=CC=C2)=NN1C3=CC=CC=C3)C4=CC=CC(C#N)=C4
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Autism spectrum disorder (ASD) is a neurodevelopmental disorder whose primary characterizations are persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests, and activities. Genetic and environmental factors have been identified as possible causes, including impaired immune responses, toxins and stressors, and neuroinflammation. Because ASD manifests itself in patients in many different ways, it has historically been difficult to treat with pharmacological therapies. During development, when the fetus experiences reduced synapse formation and delayed myelination. Therefore, drugs at present aim to correct synaptic dysfunctions, abnormalities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroinflammation. Drugs developers looking to the future aim to treat the core symptoms of ASD rather than the secondary behaviors.
Product Data
Product Data
Instruction
View handling instruction
Biological target:
CDPPB is a potent, selective and brain penetrant positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5), with an EC50 of 27 nM in Chinese hamster ovary cells expressing human mGluR5.
In vitro activity:
Treatment with CDPPB for 28 days increased neuronal viability (32.2% increase in NeuN+ cells) and reduced gliosis in CA1 region (Iba-1+ area by 31.3% and GFAP+ area by 37.5%) in transgenic animals, without inducing hepatotoxicity. However, it did not reverse cognitive deficit. Despite a four-week treatment did not prevent memory loss in aged transgenic mice, CDPPB is protective against Aβ stimulus. Reference: Neuropharmacology. 2019 Dec 1;160:107785. https://linkinghub.elsevier.com/retrieve/pii/S0028-3908(19)30343-0
In vivo activity:
The HD mouse model, BACHD, exhibits many HD features, including neuronal cell loss, htt aggregates, motor incoordination and memory impairment. However, chronic treatment of BACHD mice with CDPPB 1.5 mg/kg s.c. for 18 weeks increased the activation of cell signaling pathways important for neuronal survival, including increased AKT and ERK1/2 phosphorylation and augmented the BDNF mRNA expression. CDPPB chronic treatment was also able to prevent the neuronal cell loss that takes place in the striatum of BACHD mice and decrease htt aggregate formation. Moreover, CDPPB chronic treatment was efficient to partially ameliorate motor incoordination and to rescue the memory deficit exhibited by BACHD mice. Importantly, no toxic effects or stereotypical behavior were observed upon CDPPB chronic treatment. Thus, CDPPB is a potential drug to treat HD, preventing neuronal cell loss and htt aggregate formation and delaying HD symptoms. Reference: Neurobiol Dis. 2015 Jan;73:163-73. https://linkinghub.elsevier.com/retrieve/pii/S0969-9961(14)00252-6
Solvent mg/mL mM
Solubility
DMSO 100.0 274.42
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 364.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, Guatimosim C, Dobransky T, Ribeiro FM. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis. 2015 Jan;73:163-73. doi: 10.1016/j.nbd.2014.08.021. Epub 2014 Aug 24. PMID: 25160573. 2. Bellozi PMQ, Gomes GF, da Silva MCM, Lima IVA, Batista CRÁ, Carneiro Junior WO, Dória JG, Vieira ÉLM, Vieira RP, de Freitas RP, Ferreira CN, Candelario-Jalil E, Wyss-Coray T, Ribeiro FM, de Oliveira ACP. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology. 2019 Dec 1;160:107785. doi: 10.1016/j.neuropharm.2019.107785. Epub 2019 Sep 18. PMID: 31541651.
In vivo protocol:
1. Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, Guatimosim C, Dobransky T, Ribeiro FM. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis. 2015 Jan;73:163-73. doi: 10.1016/j.nbd.2014.08.021. Epub 2014 Aug 24. PMID: 25160573. 2. Bellozi PMQ, Gomes GF, da Silva MCM, Lima IVA, Batista CRÁ, Carneiro Junior WO, Dória JG, Vieira ÉLM, Vieira RP, de Freitas RP, Ferreira CN, Candelario-Jalil E, Wyss-Coray T, Ribeiro FM, de Oliveira ACP. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology. 2019 Dec 1;160:107785. doi: 10.1016/j.neuropharm.2019.107785. Epub 2019 Sep 18. PMID: 31541651.
1: Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, Guatimosim C, Dobransky T, Ribeiro FM. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis. 2015 Jan;73:163-73. doi: 10.1016/j.nbd.2014.08.021. Epub 2014 Aug 24. PubMed PMID: 25160573. 2: Horio M, Fujita Y, Hashimoto K. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundam Clin Pharmacol. 2013 Oct;27(5):483-8. doi: 10.1111/j.1472-8206.2012.01045.x. Epub 2012 May 17. PubMed PMID: 22594375. 3: Parmentier-Batteur S, O'Brien JA, Doran S, Nguyen SJ, Flick RB, Uslaner JM, Chen H, Finger EN, Williams TM, Jacobson MA, Hutson PH. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology. 2012 Mar;62(3):1453-60. doi: 10.1016/j.neuropharm.2010.11.013. Epub 2010 Nov 26. PubMed PMID: 21112344. 4: Fowler SW, Walker JM, Klakotskaia D, Will MJ, Serfozo P, Simonyi A, Schachtman TR. Effects of a metabotropic glutamate receptor 5 positive allosteric modulator, CDPPB, on spatial learning task performance in rodents. Neurobiol Learn Mem. 2013 Jan;99:25-31. doi: 10.1016/j.nlm.2012.10.010. Epub 2012 Nov 5. PubMed PMID: 23137441. 5: LaCrosse AL, Burrows BT, Angulo RM, Conrad PR, Himes SM, Mathews N, Wegner SA, Taylor SB, Olive MF. mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample task. Psychopharmacology (Berl). 2015 Jan;232(1):251-8. doi: 10.1007/s00213-014-3653-8. Epub 2014 Jun 29. PubMed PMID: 24973895; PubMed Central PMCID: PMC4278949. 6: Guan DF, Ren PY, Hu W, Zhang YL. The mGluR5 positive allosteric modulator CDPPB inhibits SO₂-induced protein radical formation and mitochondrial dysfunction through activation of Akt in mouse hippocampal HT22 cells. Cell Mol Neurobiol. 2015 May;35(4):573-83. doi: 10.1007/s10571-014-0153-7. Epub 2014 Dec 30. PubMed PMID: 25547390. 7: Uslaner JM, Parmentier-Batteur S, Flick RB, Surles NO, Lam JS, McNaughton CH, Jacobson MA, Hutson PH. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology. 2009 Oct-Nov;57(5-6):531-8. doi: 10.1016/j.neuropharm.2009.07.022. Epub 2009 Jul 21. PubMed PMID: 19627999. 8: Lins BR, Howland JG. Effects of the metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on rats tested with the paired associates learning task in touchscreen-equipped operant conditioning chambers. Behav Brain Res. 2016 Mar 15;301:152-60. doi: 10.1016/j.bbr.2015.12.029. Epub 2015 Dec 22. PubMed PMID: 26721467. 9: Widholm JJ, Gass JT, Cleva RM, Olive MF. The mGluR5 Positive Allosteric Modulator CDPPB Does Not Alter Extinction or Contextual Reinstatement of Methamphetamine-Seeking Behavior in Rats. J Addict Res Ther. 2011 Dec 24;S1(4). pii: 004. PubMed PMID: 22428090; PubMed Central PMCID: PMC3305267. 10: Chen T, Cao L, Dong W, Luo P, Liu W, Qu Y, Fei Z. Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC-dependent activation of MEK/ERK pathway. Neurochem Res. 2012 May;37(5):983-90. doi: 10.1007/s11064-011-0691-z. Epub 2012 Jan 10. PubMed PMID: 22228200. 11: Vardigan JD, Huszar SL, McNaughton CH, Hutson PH, Uslaner JM. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol Biochem Behav. 2010 Apr;95(2):223-9. doi: 10.1016/j.pbb.2010.01.010. Epub 2010 Feb 1. PubMed PMID: 20122952. 12: Sethna F, Wang H. Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction. Learn Mem. 2014 Nov 17;21(12):647-50. doi: 10.1101/lm.035857.114. Print 2014 Dec. PubMed PMID: 25403451; PubMed Central PMCID: PMC4236415. 13: Gass JT, Trantham-Davidson H, Kassab AS, Glen WB Jr, Olive MF, Chandler LJ. Enhancement of extinction learning attenuates ethanol-seeking behavior and alters plasticity in the prefrontal cortex. J Neurosci. 2014 May 28;34(22):7562-74. doi: 10.1523/JNEUROSCI.5616-12.2014. PubMed PMID: 24872560; PubMed Central PMCID: PMC4035518. 14: Clifton NE, Morisot N, Girardon S, Millan MJ, Loiseau F. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology (Berl). 2013 Feb;225(3):579-94. doi: 10.1007/s00213-012-2845-3. Epub 2012 Sep 16. PubMed PMID: 22983144. 15: LaCrosse AL, Taylor SB, Nemirovsky NE, Gass JT, Olive MF. mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex. CNS Neurol Disord Drug Targets. 2015;14(4):476-85. PubMed PMID: 25921744; PubMed Central PMCID: PMC4507801. 16: Wierońska JM, Kłeczek N, Woźniak M, Gruca P, Łasoń-Tyburkiewicz M, Papp M, Brański P, Burnat G, Pilc A. mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia. Neurochem Int. 2015 Sep;88:97-109. doi: 10.1016/j.neuint.2015.03.010. Epub 2015 Apr 8. PubMed PMID: 25863284. 17: Perry CJ, Reed F, Zbukvic IC, Kim JH, Lawrence AJ. The metabotropic glutamate 5 receptor is necessary for extinction of cocaine-associated cues. Br J Pharmacol. 2016 Mar;173(6):1085-94. doi: 10.1111/bph.13437. Epub 2016 Feb 18. PubMed PMID: 26784278; PubMed Central PMCID: PMC5341241. 18: Fowler SW, Ramsey AK, Walker JM, Serfozo P, Olive MF, Schachtman TR, Simonyi A. Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats. Neurobiol Learn Mem. 2011 Jan;95(1):73-9. doi: 10.1016/j.nlm.2010.11.009. Epub 2010 Nov 17. PubMed PMID: 21093598; PubMed Central PMCID: PMC3038545. 19: Kufahl PR, Hood LE, Nemirovsky NE, Barabas P, Halstengard C, Villa A, Moore E, Watterson LR, Olive MF. Positive Allosteric Modulation of mGluR5 Accelerates Extinction Learning but Not Relearning Following Methamphetamine Self-Administration. Front Pharmacol. 2012 Nov 26;3:194. doi: 10.3389/fphar.2012.00194. eCollection 2012. PubMed PMID: 23189054; PubMed Central PMCID: PMC3506114. 20: Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, Tamagnan GD, Conn PJ. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol. 2006 Aug;70(2):616-26. Epub 2006 Apr 27. PubMed PMID: 16645124.